Essa Pharma Inc
EPIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.52M
Close$
$2.33
1060.5% upside
Current Fair Value
1060.5% upsideUndervalued by 1060.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.52 Million |
|---|---|
| Enterprise Value | $-76,434,138.00 |
| Dividend Yield | $1.69 (839.96%) |
| Earnings per Share | $-0.64 |
| Beta | 1.53 |
| Outstanding Shares | 44,388,550 |
Return
| Return on Equity | -17.35% |
|---|---|
| Return on Assets | -17.10% |
| Return on Invested Capital | -19.53% |
Valuation & Multiples
| P/E Ratio | -0.47 |
|---|---|
| PEG | 1.06 |
| Price to Sales | - |
| Price to Book Ratio | 0.1 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 3.59 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4252▼ 2.60% |
|---|---|
| Total Calls | 427,600▼ 3.97% |
| Total Puts | 181,800▼ 9.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 50.74%▼ 19.04% |
|---|---|
| Total Invested | $4.30M▼ 91.92% |
| Investors Holding | 39▼ 4.00% |
ESG Score
No data
About Essa Pharma Inc
25 employeesESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.